Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Protein-Protein Interaction: Structure-Activity Studies Leading to Improved Potency

被引:132
作者
Hardcastle, Ian R. [1 ,2 ]
Liu, Junfeng [3 ]
Valeur, Eric [1 ,2 ]
Watson, Anna [1 ,2 ]
Ahmed, Shafiq U. [3 ]
Blackburn, Timothy J. [1 ,2 ]
Bennaceur, Karim [3 ]
Clegg, William [1 ,2 ]
Drummond, Catherine [3 ]
Endicott, Jane A. [4 ]
Golding, Bernard T. [1 ,2 ]
Griffin, Roger J. [1 ,2 ]
Gruber, Jan [4 ]
Haggerty, Karen [1 ,2 ]
Harrington, Ross W. [1 ,2 ]
Hutton, Claire [3 ]
Kemp, Stuart [1 ,2 ]
Lu, Xiachong [3 ]
McDonnell, James M. [4 ]
Newell, David R. [3 ]
Noble, Martin E. M. [4 ]
Payne, Sara L. [1 ,2 ]
Revill, Charlotte H. [1 ,2 ]
Riedinger, Christiane [4 ]
Xu, Qing [3 ]
Lunec, John [3 ]
机构
[1] Newcastle Univ, Newcastle Canc Ctr, No Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[2] Newcastle Univ, Sch Chem, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[3] Newcastle Univ, Newcastle Canc Ctr, No Inst Canc Res, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[4] Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England
基金
英国惠康基金;
关键词
SMALL-MOLECULE ANTAGONISTS; IN-VIVO; P53-MDM2; INTERACTION; P53; PATHWAY; MDM2; DISCOVERY; ACTIVATION; COMPLEX; CANCER; TUMORS;
D O I
10.1021/jm1011929
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Inhibition of the MDM2-p53 interaction has been shown to produce an antitumor effect, especially in MDM2 amplified tumors.. The isoindolinone scaffold has proved to be versatile for the discovery of MDM2-p53 antagonists. Optimization of previously reported inhibitors, for example, NU8231 (7) and NU8165 (49), was guided by MDM2 NMR titrations, which indicated key areas of the binding interaction to be explored. Variation of the 2-N-benzyl and 3-alkoxy substituents resulted in the identification of 3-(4-nitrobenzyl)-3-((1-(hydroxymethyl)cyclopropyl)methoxy)-2-(4-nitrobenzyl)isoindolin-1-one (74) as a potent MDM2-p53 inhibitor (IC(50) = 0.23 +/- 0.01 mu M). Resolution of the enantiomers of 74 showed that potent MDM2-p53 activity primarily resided with the (+)R-enantiomer (74a; IC(50) = 0.17 +/- 0.02 mu M). The cellular activity of key compounds has been examined in cell lines with defined p53 and MDM2 status. Compound 74a activates p53, MDM2, and p21 transcription in MDM2 amplified cells and shows moderate selectivity for wild-type p53 cell lines in growth inhibition assays.
引用
收藏
页码:1233 / 1243
页数:11
相关论文
共 27 条
[1]   Discovery and Optimization of Chromenotriazolopyrimidines as Potent Inhibitors of the Mouse Double Minute 2-Tumor Protein 53 Protein-Protein Interaction [J].
Allen, John G. ;
Bourbeau, Matthew P. ;
Wohlhieter, G. Erich ;
Bartberger, Michael D. ;
Michelsen, Klaus ;
Hungate, Randall ;
Gadwood, Robert C. ;
Gaston, Rick D. ;
Evans, Bruce ;
Mann, Larry W. ;
Matison, Michael E. ;
Schneider, Stephen ;
Huang, Xin ;
Yu, Dongyin ;
Andrews, Paul S. ;
Reichelt, Andreas ;
Long, Alexander M. ;
Yakowec, Peter ;
Yang, Evelyn Y. ;
Lee, Tani Ann ;
Oliner, Jonathan D. .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (22) :7044-7053
[2]   Inhibiting the p53-MDM2 interaction:: An important target for cancer therapy [J].
Chène, P .
NATURE REVIEWS CANCER, 2003, 3 (02) :102-109
[3]   Peptide, peptidomimetic, and small-molecule antagonists of the p53-HDM2 protein-protein interaction [J].
Fischer, PM .
INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS, 2006, 12 (01) :3-19
[4]   Mdm2 association with p53 targets its ubiquitination [J].
Fuchs, SY ;
Adler, V ;
Buschmann, T ;
Wu, XW ;
Ronai, Z .
ONCOGENE, 1998, 17 (19) :2543-2547
[5]   Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells [J].
Grasberger, BL ;
Lu, TB ;
Schubert, C ;
Parks, DJ ;
Carver, TE ;
Koblish, HK ;
Cummings, MD ;
LaFrance, LV ;
Milkiewicz, KL ;
Calvo, RR ;
Maguire, D ;
Lattanze, J ;
Franks, CF ;
Zhao, SY ;
Ramachandren, K ;
Bylebyl, GR ;
Zhang, M ;
Manthey, CL ;
Petrella, EC ;
Pantoliano, MW ;
Deckman, IC ;
Spurlino, JC ;
Maroney, AC ;
Tomczuk, BE ;
Molloy, CJ ;
Bone, RF .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (04) :909-912
[6]   Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold [J].
Hardcastle, Ian R. ;
Ahmed, Shafiq U. ;
Atkins, Helen ;
Farnie, Gillian ;
Golding, Bernard T. ;
Griffin, Roger J. ;
Guyenne, Sabrina ;
Hutton, Claire ;
Kallblad, Per ;
Kemp, Stuart J. ;
Kitching, Martin S. ;
Newell, David R. ;
Norbedo, Stefano ;
Northen, Julian S. ;
Reid, Rebecca J. ;
Saravanan, K. ;
Willems, Henriette M. G. ;
Lunec, John .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (21) :6209-6221
[7]   Mdm2 promotes the rapid degradation of p53 [J].
Haupt, Y ;
Maya, R ;
Kazaz, A ;
Oren, M .
NATURE, 1997, 387 (6630) :296-299
[8]   p53-a Jack of all trades but master of none [J].
Junttila, Melissa R. ;
Evan, Gerard I. .
NATURE REVIEWS CANCER, 2009, 9 (11) :821-829
[9]  
Kitching MS, 1999, SYNLETT, P997
[10]   Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo [J].
Koblish, HK ;
Zhao, SY ;
Franks, CF ;
Donatelli, RR ;
Tominovich, RM ;
LaFrance, LV ;
Leonard, KA ;
Gushue, JM ;
Parks, DJ ;
Calvo, RR ;
Milkiewicz, KL ;
Marugán, JJ ;
Raboisson, P ;
Cummings, MD ;
Grasberger, BL ;
Johnson, DL ;
Lu, TB ;
Molloy, CJ ;
Maroney, AC .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (01) :160-169